Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors – Aarkstore Enterprise

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.

Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.

‘Evolving Trends in Biopharmaceutical Licensing’ is a report provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.

Key Findings

• Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
• Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
• Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
• The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
• Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development

Use this report to…

• Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
• Discover the drivers and challenges facing Biopharma licensing, understand how Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
• Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
• Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.

Explore issues including…

• Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
• Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
• Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
• Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.

Discover…

• How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
• How can Biopharma companies improve their licensing strategies to ensure future growth?
• What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
• Which strategies have Biopharma used to reduce their reliance on Pharma?
• How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
• What have been the strategies of successful Biopharma and Pharma deal-makers?
• Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?

For more information, kindly visit :
http://www.aarkstore.com/reports/Evolving-Trends-in-Biopharmaceutical-Licensing-Deal-assessments-drivers-and-resistors-13949.html

Products, Technologies, Markets and Opportunities in Ophthalmology Surgical, Diagnostic, Device and Drug Markets Worldwide, Forecasts 2004 – 2012- Aarkstore Enterprise

This report details worldwide the incidence and prevalence by country/region of vision disorders (myopia, hyperopia, presbyopia, glaucoma, cataracts and retinal disease), and details the current and projected market for diagnostic and therapeutic products in the management of these vision disorders, including general vision diagnostics, diagnostics for glaucoma, corneal and retinal disorders, and therapeutic options for these disorders including use of pharmaceuticals, surgery and devices. The report details current products and technologies in use and the status of development of novel products under development. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and historic/forecast 2004-2012 (actual data for 2006/2007); competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor share data are presented for the U.S., individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), the Americas (Canada, Mexico, Brazil) and Middle East and Africa categories. The report profiles 103 companies, with detailed product development, current positions and future outlook for major competitors, and brief profiles of smaller or more development stage companies with noteworthy novel or advanced research activities in the market.

The report establishes the market size for key international markets (as indicated above) for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market (shifts in share based on technology) as technologies gain or lose relative market performance over this period.

For more information, kindly visit :
http://www.aarkstore.com/reports/Products-Technologies-Markets-and-Opportunities-in-Ophthalmology-Surgical-Diagnostic-Device-and-Drug-Markets-Worldwide-Forecasts-2004-2012-2058.html

Welcome to Aarkstore Market Research Aggregation

We specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether you’re looking for new product trends or competitive analysis of a new or existing market, Aarkstore.com has the best resource offerings and the expertise to make sure you get the right product every time. 
 
http://www.aarkstore.com

Top 200 Pharma Company Profiles By Aarkstore Enterprise

Key Findings & Highlights

- The report presents the business profile/major therapeutic segments, names of the directors, subsidiaries and agreement/alliances.
- The companies’ R&D facilities and financial highlights are given for the last five years (and updated till 2007-08 wherever information is available)
- Foreign investors will get primary information about major pharma companies in India with latest financials and other vital inputs.
- The report provides a ready reckoner which enables to understand the companies manufacturing,R&D and plant approvals

Reasons to Buy

- Access all the important information and analysis on the company in a single report
- Understand company’s overview, plant approvals,R&D etc
- Gain access to company’s adjusted five year financial data along with vital facts

For more information, kindly visit :
http://www.aarkstore.com/reports/Top-200-Pharma-Company-Profiles-12554.html

Congestive Heart Failure: Major World Markets, Volume II: Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)

Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure.

Kalorama Information’s Congestive Heart Failure, Major World Markets series looks at markets for CHF treatment in the United States, Europe, Japan and the Rest of the World. Volume II of this series looks at markets for device management of this disease in the following key categories:

• Pacemakers
• Left Ventricular Assistance Devices (LVADs)
• Implantable Cardioverter/Defibrillators (ICDs)
• Artificial Hearts

The report offers revenue breakdowns the following world markets:

• US
• Europe
• Japan
• Rest of World

In addition to market forecasts and current market information, this report contains a thorough review of products available on the market and profiles of key companies, including:

• Abbott Laboratories
• Abiomed, Inc.
• Ambu, USA
• Aortech International, plc
• Arrow International
• Atrium Medical Corporation
• ATS Medical, Inc.
• Bacchus Vascular, Inc.
• Berlin Heart AG
• Biophan Technologies, Inc.
• Biosensors International
• Biotronik, Inc.
• Boston Scientific
• CardiacAssist, Inc.
• Cardiac Science Corporation
• Cardiogenesis Corporation
• Cordis Corporation/Biologics Delivery Systems
• CoreValve, Inc.
• CryoCath Technologies, Inc.
• Cryocor, Inc.
• Datascope
• Defibtech, LLC
• Deltex Medical
• Heartlab
• Impulse Dynamics USA, Inc.
• MedicalCV, Inc.
• Medtronic, Inc.
• Orqis Medical Corporation
• Sorin SpA
• Stereotaxis, Inc.
• St. Jude Medical, Inc.
• Teleflex Medical
• Terumo Heart, Inc.
• Thoratec Corporation
• Ventracor, Inc.
• Volcano Corporation

As part of Kalorama Information’s methodology, analyst estimates are computed with intensive research of secondary data and literature, and primary research involving interviews of experts are used to test assumptions and validate models.

Product managers, business development executives, marketing executives and planners are among those who will benefit from this resource.

 

For more information, please visit : http://www.aarkstore.com/reports/Congestive-Heart-Failure-Major-World-Markets-Volume-II-Devices-Pacemaker-ICD-LVAD-and-Artificial-Heart-Markets–12940.html Or email us at press@aarkstore.com or call +919272852585.

Minimally Invasive Surgical Devices, World Market

Minimally invasive surgery (MIS) allows doctors to perform many complicated operations with a short hospital stay. It is a safe, feasible, and patient-friendly method of performing an operation.

The report includes product information, procedure volume data, world demographics; and other general issues affecting the MIS device market. Information is presented as a worldwide overview, with a focus on the US. A market summary includes market analysis by intended use and a competitive analysis of leading providers.

Additionally key company profiles are included. Revenues for each segment were gathered through both primary and secondary research methods. Additionally, the report provides detailed information regarding procedure volumes for six general areas of surgery, including:

• Orthopedic Devices
• Neurosurgery Devices
• ENT/Respiratory Devices
• Cardiovascular Devices
• Gastrointestinal System Devices
• Urological and Gynecological Devices

In this report total revenues for all minimally invasive equipment sales in each of the categories above are provided. Five year forecasts are also provided.

As this is a global survey, Revenues are provided for the following regions:

• US
• Europe
• Rest of World

Procedure volumes are available for the following surgeries for which minimally invasive equipment is utilized:

• Hip Replacement, Pinning, etc.
• Knee Repair/Fixation, Procedures
• Spinal Fusion/Spinal Hardware Removal
• Shoulder Repair/Fixation
• Lumbar Laminectomy/ Thoracic-lumbar
• Laminectomy/Diskectomy and Lumbar Decompression and Fusion
• Craniotomy (all types)
• Ventricular-Peritoneal Shunt Insertion/ Removal/Revision
• Detether Cord (adult and pediatric)
• Ethmoidectomy
• Tonsillectomy
• Thyroidectomy
• Coronary Revascularization
• Aortic Valve Replacement or Repair
• Cardiac Catheterization
• Insertion of Coronary Artery Stent(s)
• Appendectomy
• Endoscopy with or without biopsy
• Cholecystectomy
• Inguinal Herniorrhaphy
• Hysterectomy (all types)
• Prostatectomy

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 45 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives:

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007. The forecasted market analysis for 2008-2012 was largely based on demographic trends, new developments, and global expansion.

For more information, please visit : http://www.aarkstore.com/reports/Minimally-Invasive-Surgical-Devices-World-Market-12916.html Or email us at press@aarkstore.com or call +919272852585.